RenovoRx Inc (RNXT NASDAQ) stock market data APIs
$0.8114
-0.04(-4.9%)
as of November 17, 2025
Try our APIs with
free plan!
RenovoRx Inc Financial Data Overview
Price chart is built with
Anychart
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Prev. Close
0.8114
Open
0.7756
High
0.8569
Low
0.7756
52 wk Range
0.701-1.6899
Market Cap
29 470 K
Shares Outstanding
36 650 K
Revenue
928 K
EPS
-0.08
Beta
1.282
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with RenovoRx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get RenovoRx Inc data using free add-ons & libraries
Get RenovoRx Inc Fundamental Data
RenovoRx Inc Fundamental data includes:
- Net Revenue: 928 K
- EBITDA: -11 390 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-17
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
RenovoRx Inc News
New
Repare +30%, Nuvalent +9% Lead After-Hours Biotech Gains
(RTTNews) - The after-hours session on Friday, November 14, 2025, brought notable moves across several biotech and therapeutics names, as corporate updates, financial results, and strategic announceme...
RenovoRx GAAP EPS of -$0.08 in-line, revenue of $0.2M misses by $0.1M
* RenovoRx press release [https://seekingalpha.com/pr/20307315-renovorx-reports-third-quarter-2025-financial-results-including-approximately-900000-in-year] (RNXT [https://seekingalpha.com/symbol/RN...
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update
September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW,...
High Growth Tech Stocks To Watch In The US This November 2025
As the U.S. market experiences a surge in optimism following news of a potential deal to end the government shutdown, major indexes like the Nasdaq and S&P 500 have rebounded significantly, reflecting...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
